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Diagnostic markerAlthough oral cancers are generally preceded by a well-established pre-cancerous stage, there is a lack of
well-defined clinical and morphological criteria to detect and signal progression from pre-cancer to
malignant tumours. We conducted a critical review to summarize the evidence regarding aberrant
DNA methylation patterns as a potential diagnostic biomarker predicting progression. We identified all
relevant human studies published in English prior to 30th April 2015 that examined DNA methylation
(%) in oral pre-cancer by searching PubMed, Web-of-Science and Embase databases using combined
key-searches. Twenty-one studies (18-cross-sectional; 3-longitudinal) were eligible for inclusion in the
review, with sample sizes ranging from 4 to 156 affected cases. Eligible studies examined promoter
region hyper-methylation of tumour suppressor genes in pathways including cell-cycle-control
(n = 15), DNA-repair (n = 7), cell-cycle-signalling (n = 4) and apoptosis (n = 3). Hyper-methylated loci
reported in three or more studies included p16, p14, MGMT and DAPK. Two longitudinal studies reported
greater p16 hyper-methylation in pre-cancerous lesions transformed to malignancy compared to lesions
that regressed (57–63.6% versus 8–32.1%; p < 0.01). The one study that explored epigenome-wide methy-
lation patterns reported three novel hyper-methylated loci (TRHDE; ZNF454; KCNAB3). The majority of
reviewed studies were small, cross-sectional studies with poorly defined control groups and lacking
validation. Whilst limitations in sample size and study design preclude definitive conclusions, current
evidence suggests a potential utility of DNA methylation patterns as a diagnostic biomarker for oral
pre-cancer progression. Robust studies such as large epigenome-wide methylation explorations of oral
pre-cancer with longitudinal tracking are needed to validate the currently reported signals and identify
new risk-loci and the biological pathways of disease progression.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Oral cancer is a major public health problem in much of Asia, as
well as certain regions of Eastern and Western Europe, Latin Amer-
ica, Caribbean countries and Melanesia [1–3]. Although high inci-
dence zones in Asia (India, Sri Lanka, Pakistan, Bangladesh and
China–Taiwan) contribute to over one third (37.5%) of the total glo-
bal burden [1], recent trends suggest increasing incidence in the US
and in parts of Europe including the United Kingdom [4,5]. Over amillion new cases are reported every year from more developed
regions of the World [1], more so among young adults [4,5].
With a well-defined pre-cancerous stage [6–9], oral cancer
develops through a series of sequential histo-pathological changes
(normal, hyperplastic, dysplastic, and carcinoma in-situ) before
transforming to invasive disease [7,9,10]. Oral pre-cancer can be
readily detected in the oral cavity from a visual oral exam and
the oral cavity is easily accessible for cytology and biopsy confir-
mation [11]. Although detection at this early stage significantly
reduces the cancer-specific morbidity and mortality [12], oral can-
cers are mainly detected at a later stage which affects 5-year sur-
vival despite improvements in treatment aspects [4]. This is
particularly relevant for countries in high incidence zones [3,4,13].
Oral pre-cancer is clinically diverse and includes various lesions
(leukoplakia, erythroplakia and palatal lesions in reverse smokers)
2 K. Shridhar et al. / Oral Oncology 53 (2016) 1–9and conditions (submucous fibrosis, lichen planus, actinic keratosis
and discoid lupus erythematosus) that are grouped as potentially
malignant disorders (PMDs) [14]. Pre-cancerous lesions with dys-
plasia have shown a 12.3% rate of malignant transformation over
a period of 0.5–16 years [10]. The clinico-morphological dilemma
pertaining to identification, detection and early treatment of oral
pre-cancer, dictates the current ‘wait and watch’ approach for
monitoring cancer progression [6,10]. Both over- and under treat-
ment contribute to considerable patient morbidity [7,9,10]. In this
scenario where clinical and pathological investigations are very
variable in delineating pre-cancer at risk for progression, and a ser-
ies of epigenetic and genetic alterations signal disease progression,
the identification of molecular biomarkers of disease progression
could be immensely useful in the early detection of readily rever-
sible lesions, leading to more effective diagnosis and better treat-
ment outcomes [7,10].
DNA methylation is a physiologic epigenetic modification
which occurs primarily on the addition of a methyl group to a
CpG dinucleotide in the DNA sequence [15] that regulates gene
transcription [16–18]. Aberrant (more or less) methylation affects
the physiological stability of cell division [19], and is considered
a mechanism by which environmental risk factors, such as tobacco,
alcohol use and diet may influence disease risk [20–22]. Hyper-
methylation of promoter regions (CpG islands) causes silencing
of genes primarily involved in tumour suppression such as genes
in cell cycle control, DNA repair, and apoptosis pathways [18,23].
Hypo-methylation of a CpG dinucleotide in the global DNA
sequence causes activation of oncogenes such as genes in cell cycle
signalling [7,23]. DNA methylation patterns are reversible and
dynamic to adapt with changes in the environment or treatment
[18]. Dynamicity if associated with development and progression
of cancer might be particularly useful when sensitive detection is
required as in the case with early identification of oral pre-
cancer that could either progress or regress in stage of disease
[17,18,23]. Time trends of an increase or a decrease of aberrant
methylation could help predict the rate and probability of malig-
nant transformation and also a reversal of disease state respec-
tively. For these reasons, aberrant DNA methylation is thought to
be a particularly relevant candidate for evaluation as a biomarker
for its potential early diagnostic utility in oral pre-cancer progres-
sion [23].
We conducted a review of existing studies on DNA methylation
patterns in oral pre-cancer in order to understand the scope of
aberrant DNA methylation as a potential diagnostic biomarker
for disease progression, and to ascertain knowledge gaps in the lit-
erature to guide future research.Methods
We conducted a literature search in PubMed, Embase and Web
of Science to identify all relevant studies of DNA methylation on
oral pre-cancer published in the English language prior to April
30th 2015 using the following key words and their combinations
in titles and abstracts: ‘‘methylation” OR ‘‘epigenetics” AND
‘‘pre-cancer” OR ‘‘premalignant” OR ‘‘potentially malignant” OR
‘‘leukoplakia” OR ‘‘erythroplakia” OR ‘‘OSMF” OR ‘‘submucous
fibrosis” OR ‘‘lichen planus” OR ‘‘dysplasia” AND ‘‘oral” OR ‘‘head”
OR ‘‘neck” AND ‘‘humans”. All searches returned studies published
after 2001 and the last retrieval was done on 30th of April 2015.
A preliminary review of abstracts was conducted to determine
study relevance based on the following set of eligibility criteria:
(1) DNA methylation in oral pre-cancer from any bio-specimen
source (such as tissue or saliva); (2) published in English, and (3)
conducted in human subjects (not in vitro or in animals). Studies
that met these eligibility criteria were included for further reviewof the full-text article. Final inclusion was made on availability of
quantitative frequency methylation data reported as percent
methylation of samples either in cases and controls, or in cases
only. Additionally, reference lists of eligible studies were searched
for identification of relevant studies.Data extraction
The following information was extracted from each study when
possible and applicable, using a standard data collection form with
the following elements: first author, year of publication, study pop-
ulation/location, study design (classified based on whether cross-
sectional or longitudinal methylation data were presented), sam-
ple size, subject description including age, gender, tobacco/alcohol
habits, clinical and pathological description of pre-cancer (such as
leukoplakia, oral submucous fibrosis, erythroplakia, lichen planus
and histopathological features such as hyperkeratosis, hyperplasia
and dysplasia), follow-up time for longitudinal studies, source/type
of biospecimen used for methylation analysis, loci examined, func-
tion of the loci and method of methylation assay (Table 1). Percent
of aberrant methylation in cases and in controls was tabulated for
loci consistently reported in biopsy confirmed samples in 3 or
more studies (the cut-off of 3 studies as baseline criteria was based
on previous systematic review [24] and meta-analysis [25])
(Table 2). Controls were of the following types: (1) Paired samples
– biopsy confirmed normal mucosa adjacent to pre-cancer/oral
squamous cell carcinoma (OSCC); (2) samples from healthy indi-
viduals – healthy mucosa from individuals with no evidence of
pre-cancer/OSCC, or (3) pre-cancer regressed on longitudinal
follow-up. Cases were either: (1) Biopsy-confirmed dysplastic/
non-dysplastic pre-cancer, or (2) pre-cancer transformed into can-
cer on longitudinal follow-up (Table 2).Results
A total of 323 articles were retrieved from the combined key
term search on Pubmed (N = 72), Embase (N = 96) and Web-of-
Science (N = 155). After removal of duplicates, 150 distinct articles
were identified. Based on a review of titles and abstracts, 22 orig-
inal articles and 4 review articles were eligible for further review,
and full-text articles were retrieved for these. A manual search of
reference lists of the 26 studies yielded two more original research
articles and 1 review article meeting the inclusion criteria. A total
of 21 eligible original article studies were included for final review.
The geographical distribution of study locations across the globe is
shown in Fig. 1. Fig. 2 summarizes the evidence search and eligible
studies included for final review.
Table 1 summarizes key characteristics of the reviewed studies.
Eighteen cross-sectional and 3 longitudinal studies reported
hyper-methylation patterns of promoter regions of tumour sup-
pressor genes involved in cell cycle control (n = 15 studies), DNA
repair (n = 7 studies), cell cycle signalling (n = 4 studies) and apop-
totic pathways (n = 3 studies). Sample sizes ranged from 4 to 156
affected cases/regions. Only one study to date has explored
epigenome-wide methylation patterns on 10 dysplastic pre-
cancer samples. Socio-demographic and lifestyle risk factors were
inconsistently reported. A majority of studies (n = 19) used tissue
samples (paraffin fixed/fresh frozen) for methylation analysis and
2 studies used buccal samples (saliva) for the analysis. Fourteen
studies analyzed methylation patterns using a methylation-
specific PCR technique, one study used pyrosequencing, and the
remaining studies (n = 5) used methylation sensitive restriction
analysis. Epigenome-wide methylation analysis was conducted
using the Agilant Whole Human Genome Microarray 4X 44 K
platform. Only nine studies (43% of studies) reported methylation
Table 1
Characteristics of all reviewed studies (n = 21).
N Author/year/study
population
Study design Cases Controls Socio-demographic risk
factor data
Sampleanalyzed Technique Loci
examined
Pathway/function
Type Report
of
results
1 Kresty et al. [49]
USA
Longitudinal
(1997–2000)
N = 26 dysplastic lesions
(including leukoplakia and
erythroplakia)
None NA Age: 26–87 yrs
Sex: 15M/11F
Tissue MS-PCR p16INK4a
p14ARF
Cell cycle control
Cell cycle control
2 Lopez et al. [44]
Spanish
Cross-
sectional
(1) N = 19 homogenous
leukoplakia
(2) N = 15 homogenous
leukoplakia with previous
OSCC
None
None
NA
NA
Age: 25-84 yrs
Sex: 20M/14F
Saliva MS-PCR p16INK4a
p14ARF
MGMT
Cell cycle control
Cell cycle control
DNA repair
3 Youssef et al. [51]
Caucasians 89.5%
Hispanics 4%
Asians 4%
Blacks 2.5%
Cross-
sectional
N = 42 dysplastic leukoplakia
N = 82 hyperplastic
leukoplakia
N = 18 HNSCC
None
None
N = 22 normal mucosa
adjacent to HNSCC (paired
sample*)
NA
NA
Age: 23–91 yrs
Sex: 63M/61F
Tobacco – 75.6%
Alcohol – 70.7%
Tissue MS-PCR RAR-b2 Cell cycle control
4 Gao et al. [52]
Taiwan/Denmark
Cross-
sectional
N = 4 dysplastic leukoplakia
N = 34 OSCC
None
N = 7 normal oral mucosa
adjacent to OSCC
NA
Yes
Age: 35–89 yrs
Sex: 32M/6F
Tissue MS-PCR DBCCR1 Cell cycle control
5 Sengupta et al.
[53]
Indians
Cross-
sectional
N = 27 dysplastic leukoplakia
N = 123 HNSCC
N = 27 normal oral mucosa
adjacent to lesion (Paired
sample)
N = 123 normal mucosa
adjacent to HNSCC
No
NA
Age: 8–80 yrs
Sex: 103M/37F
Tobacco – 73.9%
Tissue MSRA hMLH1/2 DNA repair
6 Hall et al. [31]
UK
Longitudinal
(2000–2006)
N = 24 dysplastic
leukoplakia/erythroplakia
transformed into OSCC
N = 14 regressed dysplastic
lesions (different sampley)
Yes Long term smokers Tissue MEP p16
MGMT
CCNA1
CYGB
Cell cycle control
DNA repair
Circadian rhythm
Oxidative stress
7 Takeshima et al.
[43]
Sri Lankans
Cross-
sectional
N = 64 dysplastic leukoplakia
N = 10 OSMF
N = 10 healthy oral mucosa
from non-chewers
(different sample)
Yes Cases: Betel quid
chewers
Controls: non chewers
Tissue MS-PCR p14
p15
p16
Cell cycle control
Cell cycle control
Cell cycle control
8£ Ghosh et al. [54]
Indians
Cross-
sectional
N = 52 dysplastic leukoplakia
N = 111 HNSCC
N = 52 normal oral mucosa
adjacent to lesion (paired
sample)
N = 111 normal mucosa
adjacent to HNSCC
No
NA
Age: 22–76 yrs
Sex: 155M 33F
Tobacco – 69.6%
Tissue
Tissue
MSRA LIMD1
LTF
RASSF1A
CACNA2D2
CDC25
ASCOTIN
Cell cycle control
Immune response
Apoptosis signalling
Cell cycle control
Apoptosis signalling
9 Cao et al.** [30]
Chinese
Longitudinal
(1995–2008)
N = 22 dysplastic lesions
transformed into OSCC
N = 56 regressed dysplastic
lesions (different sample)
Yes Age: 32–77 yrs
Sex: 31M/47F
smoking – 36.8%
Tissue MS-PCR p16 Cell cycle control
10£ Ghosh et al. [48]
Indians
Cross-
sectional
N = 40 oral dysplastic
leukoplakia
N = 63 HNSCC
N = 40 normal oral mucosa
adjacent to lesion (paired
sample)
N = 63 normal mucosa
adjacent to HNSCC (paired
sample)
No
NA
Age: 22–76 yrs
Sex: 116M/39F
Tobacco – 61%
Tissue MSRA SH3GL2
p14
p15
p16
Cell cycle signalling
Cell cycle control
Cell cycle control
Cell cycle control
11 Pattani et al. [45]
Caucasians 69.6%
Afro-Americans
23%
others 7.3%
Cross-
sectional
N = 43 dysplastic
leukoplakia/erythroplakia
N = 113 pre-cancer lesions
(with/without hyperplasia)
N = 35 OSCC
None
None
NA
NA
Age: 18–90 yrs
Sex: 132M/59F
Tobacco – 69.1%
Alcohol – 72.8%
Saliva MS-PCR KIF1A
EDNRB
Unknown
Cell cycle signalling
(continued on next page)
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Table 1 (continued)
N Author/year/study
population
Study design Cases Controls Socio-demographic risk
factor data
Sampleanalyzed Technique Loci
examined
Pathway/function
Type Report
of
results
12£ Ghosh et al. [50]
Indians
Cross-
sectional
N = 54 dysplastic lesions
N = 84 HNSCC samples
N = 54 normal oral mucosa
adjacent to lesion (paired
sample)
N = 84 normal mucosa
adjacent to HNSCC (paired
sample)
No
NA
Age: 22–76 yrs
Sex: 113M/36F
Tobacco – 62%
Tissue MSRA hMLH1I
TGA9
RBSP
DNA repair
Cell cycle control
Cell cycle signalling
13 Liu et al. [33]
USA
Cross-
sectional
N = 34 dysplastic leukoplakia
N = 77 hyperkeratotic/
hyperplastic leukoplakia
N = 10OSCC
None
None
NA
NA
Age: 24-90 yrs
Sex: 59M/52F
Smoking – 80.2%
Alcohol – 70.2%
Tissue MS-PCR p16
DAPK
MGMT
GSTP1
Cell cycle control
Apoptosis signalling
DNA repair
Carcinogen metabolism
14 Silva et al. [47]
Brazilians
Cross-
sectional
N = 48 dysplastic lesions N = 24 healthy oral mucosa
(mucoceles) (different
sample)
Yes Age: 15–74 yrs
Sex: M39/F33
Tobacco – 81.8%
Alcohol – 72.7%
Tissue MS-PCR p16 CDKN2A Cell cycle control
15 Liu et al. [46]
Chinese
Cross-
sectional
N = 64 dysplastic leukoplakia
N = 13 non-dysplastic
leukoplakia
N = 32 OSCC
None
None
NA
NA
Age: 26–86 yrs
Sex: 42M/35F
Smoking – 48.6%
Alcohol – 52%
Family history – 19.5%
Spicy hot food – 18.2%
Tissue, blood,
saliva
MS-PCR DAPK Apoptosis signalling
16£ Ghosh et al. [55]
Indians
Cross-
sectional
N = 58 dysplastic lesions
N = 62 HNSCC samples
N = 58 normal oral mucosa
adjacent to lesion (paired
sample)
N = 62 normal mucosa
adjacent to HNSCC (paired
sample)
No
NA
Age: 22–76 yrs
Sex: 113M/36F
Tobacco – 62%
Tissue MSRA FANCC
PTCH1
PHF2
Cell cycle signalling
Transcription activator
17 Xu et al. [36]
Chinese
Cross-
sectional
N = 50 dysplastic OSMF
N = 60 OSCC samples
N = 50 healthy oral mucosa
from non-chewers
(different sample)
N = 50 healthy oral mucosa
from non-chewers
(different sample)
Yes
Yes
Age: 19–53 yrs
Sex: 48M/2F
Cases: Areca nut
chewers
Controls: non chewers
Tissue MS-PCR E-cadherin
COX-2
Intercellular adhesion
Inflammatory pathway
18 Dang et al. [35]
Chinese
Cross-
sectional
N = 20 non-dysplastic OLP
N = 12 OSCC samples
N = 10 healthy oral mucosa
(different sample)
N = 10 healthy oral mucosa
(different sample)
Yes
Yes
Cases: Mean age 49.6
yrs
Sex: 8M/12F
Tobacco: 30%
Alcohol: 20%
Controls: Mean age
27.8 yrs
Sex: 5M/5F
Tobacco: 30%
Alcohol: none
Tissue MS-PCR p16
miR-137
Cell cycle control
Micro-RNA
19 Towle et al. [39]
Caucasians
Cross-
sectional
N = 10 dysplastic lesions
N = 10 CIS/OSCC
N = 10 normal adjacent oral
mucosa (paired sample)
N = 10 normal adjacent oral
mucosa (paired sample)
Yes Age: 31–68 yrs
Sex: 5M/5F
Smoking – 30%
Tissue Agilant
Microarray
4X 44 K
Whole
genome
Mainly Wnt and map
kinase pathways of cell
cycle signalling
Yes
4
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K. Shridhar et al. / Oral Oncology 53 (2016) 1–9 5frequency data for control samples. The remaining studies (n = 12)
either did not report control data or did not have any controls.
Most reviewed studies used biopsy-confirmed tissue samples
and standard (validated and reproducible) methods such as methy-
lation specific or sensitive restriction analysis PCR for methylation
analysis. However, heterogeneity existed among the studies with
respect to sample size, control sampling (paired vs. different
healthy samples) and adequate reporting of percent methylation,
socio-economic and lifestyle (e.g., tobacco, alcohol) characteristics,
with less emphasis on reporting of data from controls.
Table 2 summarizes percent hyper-methylation data for cases
and controls for CpG sites of promoter regions of tumour suppres-
sor genes consistently reported in 3 or more studies. The most
commonly reported hyper-methylated loci were p16 (17.5–87.5%
in cases vs. 0–14.3% in controls); p14 (20.0–73.4% in cases vs. null
in controls); MGMT (24.6–72.7% in cases vs. 0–14.3% in controls)
and DAPK (19.5–35.2% in cases). Epigenome-wide methylation
study confirmed these loci (p16 in 50% of dysplastic cases; MGMT
in 60% of dysplastic cases and DAPK in 70% of dysplastic cases) and
identified 3 novel hyper-methylated loci as well (TRHDE, ZNF454,
KCNAB3). Two longitudinal studies observed higher p16 hyper-
methylation in pre-cancerous lesions transformed to malignancy
compared to ones that regressed (57–63.6% vs. 8–32.1%;
p < 0.01). A number of hyper-methylated loci (n = 23) were
reported only once or twice in the literature. One previous
epigenome-wide methylation study reported 90 hypomethylated
and 605 hypermethylated loci.Discussion
Epigenetic alterations such as aberrant DNA CpG methylation
patterns, which silence tumour suppressor genes and/or activate
oncogenes, are some of the earliest molecular changes in oral car-
cinogenesis [7,26,27]. These methylation patterns correlate with a
person’s genetic profile as well as environmental risk exposure
(e.g., tobacco, diet, alcohol, etc.) [26], and occur in all stages of car-
cinogenesis, including initial stages before any morphological
changes [28,29]. Thus, DNA methylation patterns stand out in their
potential as a good early diagnostic marker. These methylation
changes appear gradually and may be reversible with environmen-
tal influences, removal of risk factors or with therapeutic interven-
tions at the early stages, which also make them ideal targets for
intervention in the disease pathway (pharmacogenomics) [27].
We conducted a comprehensive critical review of studies on
DNA methylation and oral pre-cancer (n = 21 studies after exclu-
sions) to understand the current status of evidence, and to assess
the potential diagnostic utility of DNA methylation as a marker
for oral cancer progression. With the exception of one
epigenome-wide methylation profile exploration, all other studies
examined CpG sites of promoter regions of tumour suppressor
genes. Only three studies explored longitudinal methylation pat-
terns; the rest reported cross-sectional methylation profiles.
Based on the review of current evidence, a few loci involved in
cell cycle control (p16, p14), DNA repair (MGMT) and apoptosis
(DAPK) have been consistently reported in 3 or more studies and
confirmed by an epigenome-wide methylation analysis and appear
to be promising markers of choice for further evaluation. Longitu-
dinal studies have reported higher hyper-methylation (p16) for
dysplastic lesions that transformed to malignancy compared to
lesions that regressed [30,31], indicating possible dynamic alter-
ations of methylation patterns through disease progression. p16
hyper-methylation was more frequently observed during dysplas-
tic stages of pre-cancer than in non-dysplastic stages (hyperkera-
totic/hyperplastic or non-dysplastic oral pre-cancer) [32,33].
Interestingly, hyper-methylation of p16 has also been found to
Table 2
Summary of quantitative findings of the reviewed studies.
N Author/year/ ocation Cases Controls Loci identified Biological
pathway
Methylated
cases (%)
Unmethylated
cases (%)
Methylated
controls (%)
Unmethylated
controls (%)
Longitudinal studies
1 Kresty et al. [49]
Ohio, USA
Oral dysplastic lesions None p16 Cell cycle control 57.7 42.3 NR NR
p14 Cell cycle control 3.8 96.2
2 Hall et al. 2008[31]
UK
Oral dysplastic lesions
transformed into OSCC
Regressed oral dysplastic lesions p16 Cell cycle control 57.0 43.0 8.0 92.0
MGMT DNA repair 4.0 96.0 3.0 97.0
3 Cao* et al. [30]
China
Oral dysplastic lesions
transformed into OSCC
Regressed oral dysplastic lesions p16 Cell cycle control 63.6 46.4 32.1 67.9
Cross sectional studies
4 Takeshima, et al. [43]
Sri Lanka
Oral dysplastic leukoplakia Healthy oral mucosa p16 Cell cycle control 29.6 70.4 0.0 100.0
p14 Cell cycle control 73.4 26.6 0.0 100.0
Non dysplastic OSMF Healthy oral mucosa p16 Cell cycle control 70.0 30.0 0.0 100.0
p14 Cell cycle control 80.0 20.0 0.0 100.0
5 Liu et al. [33]
USA
Oral dysplastic leukoplakia None p16 Cell cycle control 41.1 58.9 NR NR
DAPK Apoptosis 35.2 64.8 NR NR
MGMT DNA repair 38.2 61.8 NR NR
Oral hyperplastic leukoplakia None p16 Cell cycle control 19.4 80.6 NR NR
DAPK Apoptosis 18.2 81.8 NR NR
MGMT DNA repair 24.6 75.4 NR NR
6 Silva et al. [47]
Brasil
Oral dysplastic leukoplakia Healthy oral mucosa p16 Cell cycle control 87.5 12.5 8.3 91.7
7 Liu et al. [46]
China
Oral dysplastic leukoplakia None DAPK Apoptosis 19.5 80.5 NR NR
8 Dang et al. [35]
China
Non dysplastic oral lichen
planus
Healthy oral mucosa p16 Cell cycle control 25.0 75.0 0.0 100.0
9 Ghosh et al. [48]
India
Oral dysplastic lesions Normal mucosa adjacent to lesions p16 Cell cycle control 17.5 82.5 NR NR
p14 Cell cycle control 20.0 80.0 NR NR
10 Bhatia et al. [32]
India
Oral dysplastic leukoplakia Healthy oral mucosa p16 cell cycle control 36.4 63.6 14.3 85.7
OSMF Healthy oral mucosa MGMT DNA repair 72.7 27.3 14.3 85.7
p16 Cell cycle control 61.5 38.5 14.3 85.7
MGMT DNA repair 43.1 53.9 14.3 85.7
OLP Healthy oral mucosa p16 cell cycle control 50.0 50.0 14.3 85.7
MGMT DNA repair 25.0 75.0 14.3 85.7
11 Towle et al [39]
Caucasians
Oral dysplastic lesions Normal mucosa adjacent to lesions p16 Cell cycle control 50.0 50.0 NR NR
MGMT DNA repair 60.0 40.0 NR NR
DAPK Apoptosis 70.0 30.0 NR NR
12 Asokan et al. [34]
India
Oral leukoplakia Healthy oral mucosa p16 Cell cycle control 60.0 40.0 0.0 100.0
MGMT DNA repair 30.0 70.0 0.0 100.0
Epigenome wide methylation study [39] reported a total of 605 hyper-methylated genes and 90 hypo-methylated genes including Wnt and MAP kinase pathway genes and 3 novel sites in TRHDE, ZNF454, KCNAB3.
NR – not reported; OSMF – oral submucous fibrosis; OLP – oral lichen planus.
* Oral dysplastic lesions included leukoplakia, oral lichen planus and discoid lupus erythmatosus.
6
K
.Shridhar
et
al./O
ral
O
ncology
53
(2016)
1–
9
Fig. 1. Reference: Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Perklin DM. GLOBOCAN 2012 v2.0 cancer incidence and mortality worldwide: IARC CancerBase No. 10
[Internet]. Lyon, France: International Agency for Research on Cancer; 2012. Available from: http://globocan.iarc.fr [accessed on 30th April 2015].
Records identified through database search (n=323) 
Duplicates (n=173) excluded  
Distinct publications (n=150) assessed for eligibility  
Excluded (n=124) on title and abstract review  
Full text publications (n=26) assessed for eligibility  
Additional publications (n=3) included based on manual 
Total full text publications (n=29) assessed for eligibility  
Excluded 
Did not present percent methylation data (n=3) 
Inappropriate study design (reviews) (n=5) 
Included for final review (n=21) original publications 
3 longitudinal and 18 cross- sectional studies 
Fig. 2. Summary of evidence search and selection for DNA methylation and oral pre-cancer (up to 30th April 2015).
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of oral and oro-pharyngeal cancers [19]. Other loci such as
E-cadherin (adhesion molecule), mi-RNA genes and various other
DNA repair genes which have been studied in oral cancers [7] are
also being evaluated in oral pre-cancer [34–36].Whilst locus-specific methylation analytical techniques primar-
ily measure promoter hyper-methylation, high-density arrays
allow aberrant (hyper- and hypo-) methylation at single sites to
be measured throughout the genome [37] in a standardized man-
ner replicable across populations [38]. The epigenome-wide
8 K. Shridhar et al. / Oral Oncology 53 (2016) 1–9methylation analysis of oral pre-cancer identified three novel loci
(TRHDE, ZNF454, KCNAB3) previously unreported in any cancer site
[39] in addition to confirming the loci in p16, MGMT and DAPK.
The functional significance of the novel sites are yet to be charac-
terized [39].
Aberrant methylation is a potential candidate for evaluation as
a biomarker for guiding patient-related clinical decisions [18],
especially for cancer sites such as the oral cavity [11], cervix [11]
and colon [40,41] where a well-established pre-cancer stage is
detected and treated. The heterogeneity in anatomical and patho-
logical aspects of disease progression associated with colon cancer
[40,41] and variations in pathological types and multiple virulent
strains of Human Papilloma Virus (HPV) causing cervical cancer
[11,42] make identification of methylation markers more compli-
cated for these sites compared to oral cancer [7].
Although our review revealed some promising leads for follow
up, many of the studies were subject to limitations in the sample
size, study design and/or the reporting of quantitative results. Most
prior studies lack data on socio-demographic and life-style risk fac-
tors. The sampling scheme was largely non-uniform, especially in
terms of control sample selection. One third of the studies either
did not report control data, or did not include any controls in their
study design. Those studies with controls varied greatly regarding
control selection (Table 1). Although paired control samples
obtained from the same individual can be helpful for controlling
potential confounding factors [39] associated with using unpaired
samples such as tobacco/betel quid use, [43] this approach does
not take into account the ‘field cancerization’ normally found in
patients of oral pre-cancer [14]. With the exception of one longitu-
dinal study wherein repeated samples on 38 affected cases were
collected (total n = 284 samples), all other studies had small sam-
ple sizes, and thus limited power for meaningful interpretation. A
large number of hyper-methylated loci were reported only once
and lacked any validation effort. Finally, the majority of published
studies use a cross-sectional design, which cannot assess tempo-
rality thus making inference regarding causality difficult. Given
these limitations, it is currently not possible to indicate strong
inference for any of the markers identified to date.
On the other hand, most published studies used standard vali-
dated bisulfite conversion and MS-PCR method to measure DNA
methylation status with adequate quality control procedures.
Additionally, the majority of studies used biopsy-confirmed tissue
samples for methylation analysis. Notably, two studies [44,45] sug-
gest that saliva could be a potential non-invasive medium for
investigation of methylation markers, although Liu et al. [46]
reported a lower yield of DAPK methylation in saliva (2.8%) com-
pared to tissue (19.5%) or blood (20.9%). Methylation patterns are
tissue specific [18] and the methylation profile of tissue may differ
from that for blood or saliva [17]. Since methylation is the cause of
differential gene expression, tissue-specific samples could reveal
accurate epigenetic methylation patterns that contribute to the
disease pathway [17]. Whole blood and saliva can also be used
for methylation analysis. Whole blood is a non-target agent with
many different cells that can have different methylation patterns
[20]. Saliva, on the other hand, has the problem of potential con-
tamination with food debris, residual cells and microorganisms
[29]. Nonetheless, some studies have shown good results with
whole blood [20] and saliva samples for highly specific salivary
bio-markers such as EDNRB and KIF1A [29]. Reasonably good cor-
relations have also been observed between tissue and blood sam-
ple results (R = 0.49, p < 0.001) [46].
Although the current evidence is inconclusive, we observed
some level of consistency in terms of loci [30–35,43,46–49] and
evidence for dynamic changes during disease progression [30,31].
A few studies also reported concomitant dysregulated protein/
mRNA expression in aberrantly methylated dysplastic oral pre-cancer [32,39,47,48,50]. Studies which analyzed methylation pat-
terns secondary to genetic alterations such as deletions [48,50]
indicated that aberrant methylation could be the earliest molecular
change signalling disease development and progression. These
data suggest that methylation patterns may serve as a potential
diagnostic biomarker for oral pre-cancer progression. Future
large-scale epigenome wide methylation studies of oral pre-
cancer with adequate replication and sequential follow-up data
to capture the dynamic variations of methylation profile can help
identify robust loci marking disease progression to guide early
diagnosis during critical windows. It is important to emphasize
the need for adequate study design, appropriate definition of con-
trols, adherence to quality control and reporting recommenda-
tions, and collection of associated socio-demographic, life-style
risk factors, and relevant clinical and histo-pathological data in
order to facilitate the development of clinically relevant markers.Conflict of interest statement
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